Q-omics provides the consensus-scored HCG20 profile across patient tissues and cancer cell-line models. HCG20 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HCG20 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, HCG20 RNA expression shows 13,388 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, LIHC, and THYM as cancer lineages where HCG20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCG20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCG20 survival associations across molecular data types. HCG20 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCG20 RNA expression–survival associations across cancer types. High HCG20 expression shows unfavorable associations in DLBC, KIRC, STAD and LIHC, but favorable associations in UVM and ACC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for HCG20 RNA expression.
This table summarizes HCG20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for HCG20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCG20 shows lower tumor expression in UCEC, PRAD and LUSC and higher tumor expression in LIHC, BRCA and STAD. The LIHC box plot shows higher HCG20 RNA expression in tumor versus normal tissue (log2 FC = +0.326, t-test p < 0.001).
This table shows molecular features associated with HCG20 in patient tissues and cancer cell lines. In patient samples, HCG20 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
